Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing findings from the VITAL trial and related meta-analyses
PubMed 36378553 · doi:10.1093/cvr/cvac172
What was done
This review summarizes randomized controlled trial evidence on marine omega-3 fatty acid (n-3 FA) supplementation for cardiovascular disease (CVD) prevention, centering on the VITAL trial. VITAL was a 2 × 2 factorial randomized trial testing n-3 FAs (1 g/day; 1.2:1 EPA:DHA ratio) versus an olive oil placebo, alongside vitamin D3 (2000 IU/day) versus placebo, over a median of 5.3 years in 25,871 US adults aged 50 and older (including 5,106 African Americans) unselected for elevated CVD risk. The paper also reviews secondary prevention trials and pooled meta-analyses.
What was found
In VITAL, n-3 FA supplementation did not significantly lower the primary composite endpoint of major CVD events (hazard ratio [HR] = 0.92, 95% CI 0.80–1.06). It significantly reduced total myocardial infarction (MI) (HR = 0.72, 95% CI 0.59–0.90), percutaneous coronary intervention (HR = 0.78, 95% CI 0.63–0.95), fatal MI (HR = 0.50, 95% CI 0.26–0.97), and recurrent hospitalization for heart failure (HR = 0.86, 95% CI 0.74–0.998), without altering first heart failure hospitalization or atrial fibrillation risk. African American participants showed greater reductions in MI and recurrent heart failure hospitalizations (P-interaction < 0.05). Broader meta-analyses confirmed coronary risk reduction without clear stroke prevention.
Why it matters
The findings indicate that while standard-dose omega-3 supplementation does not reduce broad composite cardiovascular events in an unselected general population, it selectively reduces coronary endpoints such as myocardial infarction, with potential differential benefit in specific demographic groups.
Limits
This publication is a narrative review rather than a new systematic meta-analysis. The primary composite endpoint in the featured VITAL trial was statistically non-significant, rendering individual secondary outcomes and subgroup analyses (such as African American interaction tests) hypothesis-generating and susceptible to type I error from multiple comparisons. In addition, the abstract does not report specific meta-analytic effect sizes or study counts.
Cited by
- supports In the VITAL trial, which tested an 800 mg dose of omega-3, there was a slight increase in atrial fibrillation that was not statistically significant.